This article is more than 5 years old. Information may no longer be current.
Phase 3 study of tralokinumab for atopic dermatitis begins
Click Here to Manage Email Alerts
LEO Pharma announced that the first patients have been dosed in a phase 3 study of tralokinumab for treating moderate-to-severe atopic dermatitis.
Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13, and is not currently licensed in any indication, according to a news release.
As part of the phase 3 clinical program, ECZTRA 1 is a randomized, double-blind, placebo-controlled study to measure the efficacy and safety of tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy, LEO Pharma reported.
"Advancements in the treatment of this underserved condition are necessary," Eric Simpson, MD, MCR, professor and director of clinical trials at the Oregon Health and Science University, Department of Dermatology, stated in the release. "In this phase 3 program, we will establish how tralokinumab's specific targeting of IL-13 might offer a potential new treatment for patients with this complex and chronic disease."
LEO Pharma acquired the global license to tralokinumab in skin diseases from AstraZeneca in July 2016, according to the release.
Reference: www.leo-pharma.com